No Data
No Data
Hybio Pharmaceutical Secures Chilean Medical Approval for Injectable Medication
Hybio Pharmaceutical (SHE:300199) secured approval from the Chilean National Drug Administration ANAMED to market and sell the injectable medication Terlipressin in certain markets in South America, a
Hybio Pharmaceutical (300199.SZ): Injection Terlipressin has obtained market authorization in Chile.
On July 4th, Gelunhui reported that Hybio pharmaceutical (300199.SZ) announced that recently, Shenzhen Hybio pharmaceutical co., LTD. received the approval certificate for injection terlipressin issued by the national drug management agency of Chile (ANAMED). Indications of injection terlipressin: treatment of esophageal variceal bleeding.
Hybio Pharmaceutical (300199.SZ): Hybio's Active Pharmaceutical Ingredient for Salmon Calcitonin in Wuhan has obtained the approval notice for market application.
On June 28, 2024, hybio pharmaceutical (wuhan), a wholly-owned subsidiary of Shenzhen hybio pharmaceutical co., ltd. (hereinafter referred to as hybio wuhan), received the approval letter of chemical raw materials for salmon calcitonin issued by the State Administration for drug supervision and management (acceptance number: cyhs2360154). Salmon calcitonin is one of the hormones that regulate calcium metabolism and inhibit the parathyroid gland. It can significantly reduce the loss of bone calcium in high-turnover bone diseases such as osteoporosis, dysplasia and painful neuropathic malnutrition.
Hybio Pharmaceutical (300199.SZ): Tilapornide active pharmaceutical ingredient obtains US DMF registration number.
On June 27th, Gelonhui reported that Hybio Pharmaceutical (300199.SZ) received confirmation from the US Food and Drug Administration (FDA) on June 27th, 2024 that the submitted Thiopeptide Drugmaster file (DMF) had been received.
Hybio Pharmaceutical (300199.SZ): Liraglutide Injection received tentative approval from the FDA in the USA.
On June 24th, Gelunhui reported that Hybio Pharmaceutical (300199.SZ) recently received a notice from the U.S. Food and Drug Administration (FDA). The abbreviated new drug application (ANDA), Liraglutide injection jointly filed by Hybio Pharmaceutical and Hikma Pharmaceuticals USA, Inc., has received tentative approval from the FDA. Tentative Approval indicates that the FDA has completed all the generic drug evaluation requirements, and the drug has undergone
Hybio Pharmaceutical Co., Ltd. (SZSE:300199) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
The Hybio Pharmaceutical Co., Ltd. (SZSE:300199) share price has fared very poorly over the last month, falling by a substantial 26%. Instead of being rewarded, shareholders who have already held t
No Data